Holen Sie sich die Stockscreener-App
1.02
2.00%
0.02
Handel nachbörslich:
1.04
0.02
+1.96%
Schlusskurs vom Vortag:
$1.00
Offen:
$0.99
24-Stunden-Volumen:
89,356
Relative Volume:
0.70
Marktkapitalisierung:
$49.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.47M
KGV:
-1.02
EPS:
-1
Netto-Cashflow:
$-47.50M
1W Leistung:
+17.24%
1M Leistung:
-19.05%
6M Leistung:
-36.25%
1J Leistung:
-36.65%
1-Tages-Spanne:
$0.952
$1.04
1-Wochen-Bereich:
$0.832
$1.05
52-Wochen-Spanne:
$0.821
$2.26
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Firmenname
Pmv Pharmaceuticals Inc
Sektor
Branche
Telefon
(609) 642-6664
Adresse
ONE RESEARCH WAY, PRINCETON
Vergleichen Sie PMVP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.02 | 49.44M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-12 | Eingeleitet | Jefferies | Buy |
| 2023-12-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-19 | Eingeleitet | Oppenheimer | Perform |
| 2021-08-02 | Eingeleitet | Guggenheim | Buy |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Cowen | Outperform |
| 2020-10-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Pmv Pharmaceuticals Inc Aktie (PMVP) Neueste Nachrichten
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
PMV Pharmaceuticals stock hits 52-week low at $1.32 - Investing.com
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
3 US Penny Stocks To Consider In February 2025 - simplywall.st
PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMVP's Top Executives Set to Reveal Latest Oncology Developments at Major Healthcare Conferences - StockTitan
US Penny Stocks To Watch In January 2025 - Simply Wall St
Assenagon Asset Management S.A. Reduces Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Barclays PLC Trims Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Jane Street Group LLC Sells 18,128 Shares of New Found Gold Corp. (NYSE:NFGC) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges - Investing.com India
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer - The Manila Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial - Nature
Finanzdaten der Pmv Pharmaceuticals Inc-Aktie (PMVP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):